Skip to main content
SpringerLink
Log in

Immunology of Head and Neck Cancer

  • Chapter
  • First Online:
Head and Neck Cancer

  • 2433 Accesses

Abstract

The immune system plays a key role in the development, establishment, and progression of head and neck cancer. A greater understanding of the dysregulation and evasion of the immune system in the evolution and progression of head and neck cancers provides the basis for improved therapies and outcomes for patients. Head and neck cancer evades the host’s immune system on different levels: (1) manipulation of its own immunogenicity, (2) production of immunosuppressive molecules, and (3) promotion of immunomodulatory cell types. Through the tumor’s influence on the microenvironment, the immune system can be exploited to promote metastasis, angiogenesis, and growth. In this chapter, we review basic immunology as it relates to head and neck cancer and discuss the theory of cancer immunosurveillance and immune escape. A brief overview to key components in the tumor microenvironment is provided. Current research on cytokines as biomarkers, cancer stem cells, tumor antigens, and immunotherapeutic strategies is presented.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 219.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 279.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 279.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vlock DR, Schantz SP, Fisher SG, Savage HE, Carey TE, Wolf GT. Clinical correlates of circulating immune complexes and antibody reactivity in squamous cell carcinoma of the head and neck. The Department of Veterans Affairs Laryngeal Cancer Study Group. J Clin Oncol. 1993;11:2427–33.

    CAS  PubMed  Google Scholar 

  2. Calenoff E, Cheever MA, Satam M, Dutra JC, Pelzer HJ, Kern RC, Hanson DG. Serum immunoglobulins specific for intracellular proteins of squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1995;121:183–91.

    Article  CAS  PubMed  Google Scholar 

  3. Couch ME, Ferris RL, Brennan JA, Koch WM, Jaffee EM, Leibowitz MS, Nepom GT, Erlich HA, Sidransky D. Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer. Clin Cancer Res. 2007;13:7199–206.

    Article  CAS  PubMed  Google Scholar 

  4. Rabassa ME, Croce MV, Pereyra A, Segal-Eiras A. MUC1 expression and anti-MUC1 serum immune response in head and neck squamous cell carcinoma (HNSCC): a multivariate analysis. BMC Cancer. 2006;6:253.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Yamaguchi K, Patturajan M, Trink B, Usadel H, Koch W, Jen J, Sidransky D. Circulating antibodies to p40(AIS) in the sera of respiratory tract cancer patients. Int J Cancer. 2000;89:524–8.

    Article  CAS  PubMed  Google Scholar 

  6. Tominaga O, Unsal K, Zalcman G, Soussi T. Detection of p73 antibodies in patients with various types of cancer: immunological characterization. Br J Cancer. 2001;84:57–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zumbach K, Hoffmann M, Kahn T, Bosch F, Gottschlich S, Gorogh T, Rudert H, Pawlita M. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in patients with head-and-neck squamous-cell carcinoma. Int J Cancer. 2000;85:815–8.

    Article  CAS  PubMed  Google Scholar 

  8. Shimada H, Shiratori T, Takeda A, Matsushita K, Okazumi S, Akutsu Y, Matsubara H, Nomura F, Ochiai T. Perioperative changes of serum p53 antibody titer is a predictor for survival in patients with esophageal squamous cell carcinoma. World J Surg. 2009;33:272–7.

    Article  PubMed  Google Scholar 

  9. Neuchrist C, Kornfehl J, Grasl M, Lassmann H, Kraft D, Ehrenberger K, Scheiner O. Distribution of immunoglobulins in squamous cell carcinoma of the head and neck. Int Arch Allergy Immunol. 1994;104:97–100.

    Article  CAS  PubMed  Google Scholar 

  10. Miller JF. Effect of neonatal thymectomy on the immunological responsiveness of the mouse. Proc Roy Soc B. 1962;156:2.

    Article  Google Scholar 

  11. Miller JF, Mitchell GF. Cell to cell interaction in the immune response. I. Hemolysin-forming cells in neonatally thymectomized mice reconstituted with thymus or thoracic duct lymphocytes. J Exp Med. 1968;128:801–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Mitchell GF, Miller JF. Cell to cell interaction in the immune response. II. The source of hemolysin-forming cells in irradiated mice given bone marrow and thymus or thoracic duct lymphocytes. J Exp Med. 1968;128:821–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Masopust D, Vezys V, Wherry EJ, Ahmed R. A brief history of CD8 T cells. Eur J Immunol. 2007;37 Suppl 1:S103–10.

    Article  CAS  PubMed  Google Scholar 

  14. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol. 1989;7:145–73.

    Article  CAS  PubMed  Google Scholar 

  15. Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007;19:362–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bergmann C, Strauss L, Wang Y, Szczepanski MJ, Lang S, Johnson JT, Whiteside TL. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res. 2008;14:3706–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:6301–11.

    Article  CAS  PubMed  Google Scholar 

  18. Herberman RB, Nunn ME, Holden HT, Lavrin DH. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer. 1975;16:230–9.

    Article  CAS  PubMed  Google Scholar 

  19. Miller JS. The biology of natural killer cells in cancer, infection, and pregnancy. Exp Hematol. 2001;29:1157–68.

    Article  CAS  PubMed  Google Scholar 

  20. Herberman RB, Holden HT. Natural cell-mediated immunity. Adv Cancer Res. 1978;27:305–77.

    Article  CAS  PubMed  Google Scholar 

  21. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991–8.

    Article  CAS  PubMed  Google Scholar 

  22. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol. 2002;20:323–70.

    Article  CAS  PubMed  Google Scholar 

  23. Gillison ML. Oropharyngeal cancer: a potential consequence of concomitant HPV and HIV infection. Curr Opin Oncol. 2009;21:439–44.

    Article  PubMed  Google Scholar 

  24. Jain A, Reyes J, Kashyap R, Rohal S, Abu-Elmagd K, Starzl T, Fung J. What have we learned about primary liver transplantation under tacrolimus immunosuppression? Long-term follow-up of the first 1000 patients. Ann Surg. 1999;230:441–8. discussion 448–449.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Birkeland SA, Storm HH, Lamm LU, Barlow L, Blohme I, Forsberg B, Eklund B, Fjeldborg O, Friedberg M, Frodin L, et al. Cancer risk after renal transplantation in the Nordic countries, 1964–1986. Int J Cancer. 1995;60:183–9.

    Article  CAS  PubMed  Google Scholar 

  26. Shankaran V, Ikeda H, Bruce AT, White JM, Swanson PE, Old LJ, Schreiber RD. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001;410:1107–11.

    Article  CAS  PubMed  Google Scholar 

  27. Grandis JR, Falkner DM, Melhem MF, Gooding WE, Drenning SD, Morel PA. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res. 2000;6:2794–802.

    CAS  PubMed  Google Scholar 

  28. Mizukami Y, Kono K, Maruyama T, Watanabe M, Kawaguchi Y, Kamimura K, Fujii H. Downregulation of HLA Class I molecules in the tumour is associated with a poor prognosis in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2008;99:1462–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ogino T, Shigyo H, Ishii H, Katayama A, Miyokawa N, Harabuchi Y, Ferrone S. HLA class I antigen down-regulation in primary laryngeal squamous cell carcinoma lesions as a poor prognostic marker. Cancer Res. 2006;66:9281–9.

    Article  CAS  PubMed  Google Scholar 

  30. Ferris RL, Whiteside TL, Ferrone S. Immune escape associated with functional defects in antigen-processing machinery in head and neck cancer. Clin Cancer Res. 2006;12:3890–5.

    Article  CAS  PubMed  Google Scholar 

  31. Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL. Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol. 2006;176:3402–9.

    Article  CAS  PubMed  Google Scholar 

  32. Gastman BR, Atarshi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, Whiteside TL. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59:5356–64.

    CAS  PubMed  Google Scholar 

  33. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8:467–77.

    Article  CAS  PubMed  Google Scholar 

  34. Zandberg DP, Strome SE. The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck. Oral Oncol. 2014;50:627–32.

    Article  CAS  PubMed  Google Scholar 

  35. Sega EI, Leveson-Gower DB, Florek M, Schneidawind D, Luong RH, Negrin RS. Role of lymphocyte activation gene-3 (Lag-3) in conventional and regulatory T cell function in allogeneic transplantation. PLoS One. 2014;9, e86551.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  36. Yang ZZ, Grote DM, Ziesmer SC, Niki T, Hirashima M, Novak AJ, Witzig TE, Ansell SM. IL-12 upregulates TIM-3 expression and induces T cell exhaustion in patients with follicular B cell non-Hodgkin lymphoma. J Clin Invest. 2012;122:1271–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, Scheu S, Pfeffer K, Ware CF, Murphy TL, Murphy KM. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol. 2005;6:90–8.

    Article  CAS  PubMed  Google Scholar 

  38. Wang Y, Subudhi SK, Anders RA, Lo J, Sun Y, Blink S, Wang Y, Wang J, Liu X, Mink K, et al. The role of herpesvirus entry mediator as a negative regulator of T cell-mediated responses. J Clin Invest. 2005;115:711–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Jebreel A, Mistry D, Loke D, Dunn G, Hough V, Oliver K, Stafford N, Greenman J. Investigation of interleukin 10, 12 and 18 levels in patients with head and neck cancer. J Laryngol Otol. 2007;121:246–52.

    Article  CAS  PubMed  Google Scholar 

  40. Moutsopoulos NM, Wen J, Wahl SM. TGF-beta and tumors–an ill-fated alliance. Curr Opin Immunol. 2008;20:234–40.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lu SL, Reh D, Li AG, Woods J, Corless CL, Kulesz-Martin M, Wang XJ. Overexpression of transforming growth factor beta1 in head and neck epithelia results in inflammation, angiogenesis, and epithelial hyperproliferation. Cancer Res. 2004;64:4405–10.

    Article  CAS  PubMed  Google Scholar 

  42. Cheng F, Wang HW, Cuenca A, Huang M, Ghansah T, Brayer J, Kerr WG, Takeda K, Akira S, Schoenberger SP, et al. A critical role for Stat3 signaling in immune tolerance. Immunity. 2003;19:425–36.

    Article  CAS  PubMed  Google Scholar 

  43. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, Wolf GT, Teknos TN. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113:750–7.

    Article  PubMed  Google Scholar 

  44. Hoffmann TK, Muller-Berghaus J, Ferris RL, Johnson JT, Storkus WJ, Whiteside TL. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin Cancer Res. 2002;8:1787–93.

    PubMed  Google Scholar 

  45. Murray PJ. STAT3-mediated anti-inflammatory signalling. Biochem Soc Trans. 2006;34:1028–31.

    Article  CAS  PubMed  Google Scholar 

  46. Sun Y, Chin YE, Weisiger E, Malter C, Tawara I, Toubai T, Gatza E, Mascagni P, Dinarello CA, Reddy P. Cutting edge: negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. J Immunol. 2009;182:5899–903.

    Article  CAS  PubMed  Google Scholar 

  47. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell. 2009;15:114–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Pallandre JR, Brillard E, Crehange G, Radlovic A, Remy-Martin JP, Saas P, Rohrlich PS, Pivot X, Ling X, Tiberghien P, Borg C. Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity. J Immunol. 2007;179:7593–604.

    Article  CAS  PubMed  Google Scholar 

  49. Snyderman CH, Milanovich M, Wagner RL, Johnson JT. Prognostic significance of prostaglandin E2 production in fresh tissues of head and neck cancer patients. Head Neck. 1995;17:108–13.

    Article  CAS  PubMed  Google Scholar 

  50. Camacho M, Leon X, Fernandez-Figueras MT, Quer M, Vila L. Prostaglandin E(2) pathway in head and neck squamous cell carcinoma. Head Neck. 2008;30:1175–81.

    Article  PubMed  Google Scholar 

  51. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23:144–50.

    Article  CAS  PubMed  Google Scholar 

  52. Seiwert TY, Cohen EE. Targeting angiogenesis in head and neck cancer. Semin Oncol. 2008;35:274–85.

    Article  PubMed  Google Scholar 

  53. Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA. Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther. 2007;7:449–60.

    Article  CAS  PubMed  Google Scholar 

  54. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4:941–52.

    Article  CAS  PubMed  Google Scholar 

  55. Pak AS, Wright MA, Matthews JP, Collins SL, Petruzzelli GJ, Young MR. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin Cancer Res. 1995;1:95–103.

    CAS  PubMed  Google Scholar 

  56. Koizumi K, Hojo S, Akashi T, Yasumoto K, Saiki I. Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci. 2007;98:1652–8.

    Article  CAS  PubMed  Google Scholar 

  57. Ding Y, Shimada Y, Maeda M, Kawabe A, Kaganoi J, Komoto I, Hashimoto Y, Miyake M, Hashida H, Imamura M. Association of CC chemokine receptor 7 with lymph node metastasis of esophageal squamous cell carcinoma. Clin Cancer Res. 2003;9:3406–12.

    CAS  PubMed  Google Scholar 

  58. Wang J, Xi L, Hunt JL, Gooding W, Whiteside TL, Chen Z, Godfrey TE, Ferris RL. Expression pattern of chemokine receptor 6 (CCR6) and CCR7 in squamous cell carcinoma of the head and neck identifies a novel metastatic phenotype. Cancer Res. 2004;64:1861–6.

    Article  CAS  PubMed  Google Scholar 

  59. Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, Chen ZG, Ferris RL. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and prosurvival pathways in head and neck cancer cells independent of EGFR. Oncogene. 2005;24:5897–904.

    Article  CAS  PubMed  Google Scholar 

  60. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature. 2006;441:431–6.

    Article  CAS  PubMed  Google Scholar 

  61. Van Waes C, Yu M, Nottingham L, Karin M. Inhibitor-kappaB kinase in tumor promotion and suppression during progression of squamous cell carcinoma. Clin Cancer Res. 2007;13:4956–9.

    Article  PubMed  CAS  Google Scholar 

  62. Anto RJ, Mukhopadhyay A, Shishodia S, Gairola CG, Aggarwal BB. Cigarette smoke condensate activates nuclear transcription factor-kappaB through phosphorylation and degradation of IkappaB(alpha): correlation with induction of cyclooxygenase-2. Carcinogenesis. 2002;23:1511–8.

    Article  CAS  PubMed  Google Scholar 

  63. Lin SC, Lu SY, Lee SY, Lin CY, Chen CH, Chang KW. Areca (betel) nut extract activates mitogen-activated protein kinases and NF-kappaB in oral keratinocytes. Int J Cancer. 2005;116:526–35.

    Article  CAS  PubMed  Google Scholar 

  64. Bancroft CC, Chen Z, Yeh J, Sunwoo JB, Yeh NT, Jackson S, Jackson C, Van Waes C. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-kappaB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer. 2002;99:538–48.

    Article  CAS  PubMed  Google Scholar 

  65. Ferris RL, Grandis JR. NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. Clin Cancer Res. 2007;13:5663–4.

    Article  CAS  PubMed  Google Scholar 

  66. Allen CT, Ricker JL, Chen Z, Van Waes C. Role of activated nuclear factor-kappaB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head Neck. 2007;29:959–71.

    Article  PubMed  Google Scholar 

  67. Soylu L, Ozcan C, Cetik F, Paydas S, Kiroglu M, Aydogan B, Sargin O, Ozsahinoglu C, Seyrek E. Serum levels of tumor necrosis factor in squamous cell carcinoma of the head and neck. Am J Otolaryngol. 1994;15:281–5.

    Article  CAS  PubMed  Google Scholar 

  68. Jablonska E, Piotrowski L, Grabowska Z. Serum Levels of IL-1b, IL-6, TNF-a, sTNF-RI and CRP in Patients with Oral Cavity Cancer. Pathol Oncol Res. 1997;3:126–9.

    Article  PubMed  Google Scholar 

  69. Gokhale AS, Haddad RI, Cavacini LA, Wirth L, Weeks L, Hallar M, Faucher J, Posner MR. Serum concentrations of interleukin-8, vascular endothelial growth factor, and epidermal growth factor receptor in patients with squamous cell cancer of the head and neck. Oral Oncol. 2005;41:70–6.

    Article  CAS  PubMed  Google Scholar 

  70. Linkov F, Lisovich A, Yurkovetsky Z, Marrangoni A, Velikokhatnaya L, Nolen B, Winans M, Bigbee W, Siegfried J, Lokshin A, Ferris RL. Early detection of head and neck cancer: development of a novel screening tool using multiplexed immunobead-based biomarker profiling. Cancer Epidemiol Biomarkers Prev. 2007;16:102–7.

    Article  CAS  PubMed  Google Scholar 

  71. Allen C, Duffy S, Teknos T, Islam M, Chen Z, Albert PS, Wolf G, Van Waes C. Nuclear factor-kappaB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin Cancer Res. 2007;13:3182–90.

    Article  CAS  PubMed  Google Scholar 

  72. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, Herbst RS, Johnson BE, Heymach JV. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res. 2009;15:3600–9.

    Article  CAS  PubMed  Google Scholar 

  73. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 2009;182:4499–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Umansky V, Sevko A. Overcoming immunosuppression in the melanoma microenvironment induced by chronic inflammation. Cancer Immunol Immunother. 2012;61:275–82.

    Article  CAS  PubMed  Google Scholar 

  75. Grizzle WE, Xu X, Zhang S, Stockard CR, Liu C, Yu S, Wang J, Mountz JD, Zhang HG. Age-related increase of tumor susceptibility is associated with myeloid-derived suppressor cell mediated suppression of T cell cytotoxicity in recombinant inbred BXD12 mice. Mech Ageing Dev. 2007;128:672–80.

    Article  CAS  PubMed  Google Scholar 

  76. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995;155:1151–64.

    CAS  PubMed  Google Scholar 

  77. Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, Vanini V, Romagnani P, et al. Human CD8+CD25+ thymocytes share phenotypic and functional features with CD4+CD25+ regulatory thymocytes. Blood. 2003;102:4107–14.

    Article  CAS  PubMed  Google Scholar 

  78. Alhamarneh O, Amarnath SM, Stafford ND, Greenman J. Regulatory T cells: what role do they play in antitumor immunity in patients with head and neck cancer? Head Neck. 2008;30:251–61.

    Article  PubMed  Google Scholar 

  79. Ralainirina N, Poli A, Michel T, Poos L, Andres E, Hentges F, Zimmer J. Control of NK cell functions by CD4+CD25+ regulatory T cells. J Leukoc Biol. 2007;81:144–53.

    Article  CAS  PubMed  Google Scholar 

  80. Strauss L, Bergmann C, Szczepanski M, Gooding W, Johnson JT, Whiteside TL. A unique subset of CD4+CD25highFoxp3+ T cells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin Cancer Res. 2007;13:4345–54.

    Article  CAS  PubMed  Google Scholar 

  81. Strauss L, Bergmann C, Whiteside TL. Functional and phenotypic characteristics of CD4+CD25highFoxp3+ Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer. 2007;121:2473–83.

    Article  CAS  PubMed  Google Scholar 

  82. Sakakura K, Chikamatsu K, Takahashi K, Whiteside TL, Furuya N. Maturation of circulating dendritic cells and imbalance of T-cell subsets in patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother. 2006;55:151–9.

    Article  PubMed  Google Scholar 

  83. Chikamatsu K, Sakakura K, Whiteside TL, Furuya N. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck. Head Neck. 2007;29:120–7.

    Article  PubMed  Google Scholar 

  84. Badoual C, Hans S, Rodriguez J, Peyrard S, Klein C, Agueznay Nel H, Mosseri V, Laccourreye O, Bruneval P, Fridman WH, et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin Cancer Res. 2006;12:465–72.

    Article  CAS  PubMed  Google Scholar 

  85. Boucek J, Mrkvan T, Chovanec M, Kuchar M, Betka J, Boucek V, Hladikova M, Betka J, Eckschlager T, Rihova B. Regulatory T cells and their prognostic value for patients with squamous cell carcinoma of the head and neck. J Cell Mol Med. 2010;14:426–33.

    Article  CAS  PubMed  Google Scholar 

  86. Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014;105:1–8.

    Article  CAS  PubMed  Google Scholar 

  87. Tang C, Ang BT, Pervaiz S. Cancer stem cell: target for anti-cancer therapy. FASEB J. 2007;21:3777–85.

    Article  CAS  PubMed  Google Scholar 

  88. Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, Weissman IL, Clarke MF, Ailles LE. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007;104:973–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, Bergh J, Liu A, Miu K, Watnick RS, Reinhardt F, et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell. 2008;134:62–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Mack B, Gires O. CD44s and CD44v6 expression in head and neck epithelia. PLoS One. 2008;3, e3360.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  91. Chen YC, Chen YW, Hsu HS, Tseng LM, Huang PI, Lu KH, Chen DT, Tai LK, Yung MC, Chang SC, et al. Aldehyde dehydrogenase 1 is a putative marker for cancer stem cells in head and neck squamous cancer. Biochem Biophys Res Commun. 2009;385:307–13.

    Article  CAS  PubMed  Google Scholar 

  92. Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, Shin DM, Donnenberg VS, Whiteside TL, DeLeo AB. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 2007;67:10538–45.

    Article  CAS  PubMed  Google Scholar 

  93. Lathers DM, Young MR. Increased aberrance of cytokine expression in plasma of patients with more advanced squamous cell carcinoma of the head and neck. Cytokine. 2004;25:220–8.

    Article  CAS  PubMed  Google Scholar 

  94. Yan J, Reichenbach DK, Corbitt N, Hokey DA, Ramanathan MP, McKinney KA, Weiner DB, Sewell D. Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen. Vaccine. 2009;27:431–40.

    Article  CAS  PubMed  Google Scholar 

  95. Victora GD, Socorro-Silva A, Volsi EC, Abdallah K, Lima FD, Smith RB, Moyses RA, Zarate-Blades CR, Michaluart P, Silva CL, et al. Immune response to vaccination with DNA-Hsp65 in a phase I clinical trial with head and neck cancer patients. Cancer Gene Ther. 2009;16:598–608.

    Article  CAS  PubMed  Google Scholar 

  96. Sewell DA, Pan ZK, Paterson Y. Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors. Vaccine. 2008;26:5315–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  97. Davidson EJ, Faulkner RL, Sehr P, Pawlita M, Smyth LJ, Burt DJ, Tomlinson AE, Hickling J, Kitchener HC, Stern PL. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine. 2004;22:2722–9.

    Article  CAS  PubMed  Google Scholar 

  98. Albarran YCA, de la Garza A, Cruz Quiroz BJ, Vazquez Zea E, Diaz Estrada I, Mendez Fuentez E, Lopez Contreras M, Andrade-Manzano A, Padilla S, Varela AR, Rosales R. MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study. BioDrugs. 2007;21:47–59.

    Article  Google Scholar 

  99. Karcher J, Dyckhoff G, Beckhove P, Reisser C, Brysch M, Ziouta Y, Helmke BH, Weidauer H, Schirrmacher V, Herold-Mende C. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 2004;64:8057–61.

    Article  CAS  PubMed  Google Scholar 

  100. Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, Argiris A, Gooding W, Butterfield LH, Whiteside TL, Ferris RL. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014;20:2433–44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Weise JB, Csiszar K, Gottschlich S, Hoffmann M, Schmidt A, Weingartz U, Adamzik I, Heiser A, Kabelitz D, Ambrosch P, Gorogh T. Vaccination strategy to target lysyl oxidase-like 4 in dendritic cell based immunotherapy for head and neck cancer. Int J Oncol. 2008;32:317–22.

    CAS  PubMed  Google Scholar 

  102. Stephenson RM, Lim CM, Matthews M, Dietsch G, Hershberg R, Ferris RL. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells. Cancer Immunol Immunother. 2013;62:1347–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  103. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials. 2013;34:8690–707.

    Article  CAS  PubMed  Google Scholar 

  104. Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, Drenning SD, Tweardy DJ. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 1998;90:824–32.

    Article  CAS  PubMed  Google Scholar 

  105. Bauman JE, Ferris RL. Integrating novel therapeutic monoclonal antibodies into the management of head and neck cancer. Cancer. 2014;120:624–32.

    Article  CAS  PubMed  Google Scholar 

  106. Lopez-Albaitero A, Ferris RL. Immune activation by epidermal growth factor receptor specific monoclonal antibody therapy for head and neck cancer. Arch Otolaryngol Head Neck Surg. 2007;133:1277–81.

    Article  PubMed  Google Scholar 

  107. Lopez-Albaitero A, Lee SC, Morgan S, Grandis JR, Gooding WE, Ferrone S, Ferris RL. Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells. Cancer Immunol Immunother. 2009;58:1853–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  108. Dechant M, Weisner W, Berger S, Peipp M, Beyer T, Schneider-Merck T, Lammerts van Bueren JJ, Bleeker WK, Parren PW, van de Winkel JG, Valerius T. Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies. Cancer Res. 2008;68:4998–5003.

    Article  CAS  PubMed  Google Scholar 

  109. Dhodapkar MV, Dhodapkar KM, Li Z. Role of chaperones and FcgammaR in immunogenic death. Curr Opin Immunol. 2008;20:512–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  110. Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res. 2007;13:5133–43.

    Article  CAS  PubMed  Google Scholar 

  111. Banerjee D, Matthews P, Matayeva E, Kaufman JL, Steinman RM, Dhodapkar KM. Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcgammaRs on human dendritic cells. J Immunother. 2008;31:113–20.

    Article  CAS  PubMed  Google Scholar 

  112. Lee SC, Srivastava RM, Lopez-Albaitero A, Ferrone S, Ferris RL. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity. Immunol Res. 2011;50:248–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  113. Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. Trends Immunol. 2004;25:47–52.

    Article  CAS  PubMed  Google Scholar 

  114. Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, Carson III WE. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines. Clin Cancer Res. 2007;13:6419–28.

    Article  CAS  PubMed  Google Scholar 

  115. Mailliard RB, Son YI, Redlinger R, Coates PT, Giermasz A, Morel PA, Storkus WJ, Kalinski P. Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol. 2003;171:2366–73.

    Article  CAS  PubMed  Google Scholar 

  116. Lucas M, Schachterle W, Oberle K, Aichele P, Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity. 2007;26:503–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Moretta L, Ferlazzo G, Bottino C, Vitale M, Pende D, Mingari MC, Moretta A. Effector and regulatory events during natural killer-dendritic cell interactions. Immunol Rev. 2006;214:219–28.

    Article  CAS  PubMed  Google Scholar 

  118. El-Shami K, Tirosh B, Bar-Haim E, Carmon L, Vadai E, Fridkin M, Feldman M, Eisenbach L. MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitope. Eur J Immunol. 1999;29:3295–301.

    Article  CAS  PubMed  Google Scholar 

  119. Lee JC, Lee KM, Kim DW, Heo DS. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004;172:7335–40.

    Article  CAS  PubMed  Google Scholar 

  120. Yao M, Galanopoulos N, Lavertu P, Fu P, Gibson M, Argiris A, Rezaee R, Zender C, Wasman J, Machtay M, Savvides P. A phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neck. Head Neck. 2015;37(11):1665–71.

    Google Scholar 

  121. Melero I, Hirschhorn-Cymerman D, Morales-Kastresana A, Sanmamed MF, Wolchok JD. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res. 2013;19:1044–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Otorhinolaryngology, University Hospital Essen, Essen, Germany

    Benjamin A. Kansy MD

  2. Otolaryngology: Head and Neck Surgery, Loma Linda University, Loma Linda, CA, USA

    Steve C. Lee MD, PhD

  3. Department of Otolaryngology—Head and Neck Surgery, University of Pittsburgh Cancer Institute, 5117 Centre Avenue, Suite 2.26, Pittsburgh, PA, 15213, USA

    Robert L. Ferris MD, PhD

Authors
  1. Benjamin A. Kansy MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steve C. Lee MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert L. Ferris MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Robert L. Ferris MD, PhD .

Editor information

Editors and Affiliations

  1. Department of Radio-Oncology, Genolier Swiss Medical Network, Genolier, Switzerland

    Jacques Bernier

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Kansy, B.A., Lee, S.C., Ferris, R.L. (2016). Immunology of Head and Neck Cancer. In: Bernier, J. (eds) Head and Neck Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-27601-4_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27601-4_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-27599-4

  • Online ISBN: 978-3-319-27601-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation